Clearside Biomedical Files Q2 2024 10-Q
Ticker: CLSDQ · Form: 10-Q · Filed: Aug 12, 2024 · CIK: 1539029
| Field | Detail |
|---|---|
| Company | Clearside Biomedical, Inc. (CLSDQ) |
| Form Type | 10-Q |
| Filed Date | Aug 12, 2024 |
| Risk Level | medium |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, financials, biotech
TL;DR
Clearside Bio's Q2 10-Q is in. Check financials and ops.
AI Summary
Clearside Biomedical, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported on its financial performance and business operations. Key events and financial data from the quarter are detailed within the filing.
Why It Matters
This filing provides investors and stakeholders with an update on Clearside Biomedical's financial health and operational progress during the second quarter of 2024.
Risk Assessment
Risk Level: medium — As a pharmaceutical company, Clearside Biomedical faces inherent risks related to drug development, regulatory approvals, and market competition.
Key Numbers
- 20240630 — Reporting Period End Date (Indicates the end of the fiscal quarter covered by the report.)
- 20240812 — Filing Date (The date the 10-Q was officially submitted to the SEC.)
Key Players & Entities
- Clearside Biomedical, Inc. (company) — Filer of the 10-Q
- 20240630 (date) — End of the reporting period
- Bausch Health Ireland Limited (company) — Party to an agreement with Clearside
- Arctic Visions Limited (company) — Party to a license arrangement
- Biocryst License Agreement (document) — Related party agreement
FAQ
What is the reporting period for this 10-Q filing?
The Conformed Period of Report is 20240630, meaning the filing covers the period ending June 30, 2024.
When was this 10-Q filed with the SEC?
This 10-Q was filed on 20240812.
What is Clearside Biomedical's Standard Industrial Classification?
Clearside Biomedical's SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Are there any specific license arrangements mentioned?
Yes, the filing mentions a license arrangement with Arctic Visions Limited, and a Biocryst License Agreement.
Who is mentioned as a party in relation to a specific product or agreement?
Bausch Health Ireland Limited is mentioned in relation to the Xipere product for the period 2024-01-01 to 2024-06-30.
Filing Stats: 4,486 words · 18 min read · ~15 pages · Grade level 17.5 · Accepted 2024-08-12 16:30:24
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 per share CLSD The Nasdaq Stock Mar
Filing Documents
- clsd-20240630.htm (10-Q) — 1340KB
- clsd-ex10_1.htm (EX-10.1) — 17KB
- clsd-ex10_2.htm (EX-10.2) — 108KB
- clsd-ex31_1.htm (EX-31.1) — 14KB
- clsd-ex31_2.htm (EX-31.2) — 13KB
- clsd-ex32_1.htm (EX-32.1) — 9KB
- img142401494_0.jpg (GRAPHIC) — 108KB
- 0000950170-24-095489.txt ( ) — 6864KB
- clsd-20240630.xsd (EX-101.SCH) — 1154KB
- clsd-20240630_htm.xml (XML) — 977KB
- FINANCIAL INFORMATION
PART I - FINANCIAL INFORMATION Item 1.
Financial Statements (unaudited)
Financial Statements (unaudited) Consolidated Balance Sheets as of June 30, 2024 and December 31, 2023 3 Consolidated Statements of Operations and Comprehensive Loss for the three and six months ended June 30, 2024 and 2023 4 Consolidated Statements of Stockholders' (Deficit) Equity for the three and six months ended June 30, 2024 and 2023 5 Consolidated Statements of Cash Flows for the six months ended June 30, 2024 and 2023 6 Notes to the Consolidated Financial Statements 7 Item 2.
Management's Discussion and Analysis of Financial Condition and Results of Operations
Management's Discussion and Analysis of Financial Condition and Results of Operations 18 Item 3.
Quantitative and Qualitative Disclosures About Market Risk
Quantitative and Qualitative Disclosures About Market Risk 27 Item 4.
Controls and Procedures
Controls and Procedures 27
- OTHER INFORMATION
PART II - OTHER INFORMATION Item 1.
Legal Proceedings
Legal Proceedings 28 Item 1A
Risk Factors
Risk Factors 28 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 28 Item 5. Other Information 28 Item 6. Exhibits 29
– FINANCIAL INFORMATION
PART I – FINANCIAL INFORMATION
Financial Statements
Item 1. Financial Statements CLEARSIDE BIOMEDICAL, INC. C onsolidated Balance Sheets (in thousands, except share and per share data) (unaudited) June 30, 2024 December 31, 2023 Assets Current assets: Cash and cash equivalents $ 18,238 $ 28,920 Short-term investments 11,122 — Accounts receivable — 170 Prepaid expenses 364 722 Other current assets 44 311 Total current assets 29,768 30,123 Property and equipment, net 3,400 2,996 Operating lease right-of-use asset 736 869 Other assets 30 30 Total assets $ 33,934 $ 34,018 Liabilities and stockholders' (deficit) equity Current liabilities: Accounts payable (includes $ 40 and $ 331 to a related party as of June 30, 2024 and December 31, 2023, respectively) $ 1,576 $ 2,205 Accrued liabilities (includes $ 416 and $ 215 to a related party as of June 30, 2024 and December 31, 2023, respectively) 3,703 4,169 Current portion of operating lease liabilities 370 364 Deferred revenue 225 75 Total current liabilities 5,874 6,813 Liability related to the sales of future royalties, net 46,731 41,988 Warrant liabilities 9,121 — Operating lease liabilities 493 649 Other non-current liabilities — 480 Total liabilities 62,219 49,930 Commitments and contingencies Stockholders' (deficit) equity: Preferred stock, $ 0.001 par value; 10,000,000 shares authorized and no shares issued at June 30, 2024 and December 31, 2023 — — Common stock, $ 0.001 par value; 200,000,000 shares authorized at June 30, 2024 and December 31, 2023; 74,731,139 and 62,850,841 shares issued and outstanding at June 30, 2024 and December 31, 2023, respectively 74 63 Additional paid-in capital 311,922 304,948 Accumulated deficit ( 340,280 ) ( 320,923 ) Accumulated other comprehensive loss ( 1 ) — Total stockholders' deficit ( 28,285 ) ( 15,912 ) Total liabilities and stoc